Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15829266 | 0.88 | CRBN (0.44) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL13373460 | 0.81 | — | — | |
| SCHEMBL30731334 | 0.76 | NPC1 (0.37) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL6339658 | 0.69 | GSK3B (0.30) | — | |
| SCHEMBL28881580 | 0.68 | DAPK3 (0.36) | CRBNCCNA2CDK2CCNA1 | |
| SCHEMBL11835957 | 0.67 | CRBN (0.40) | CRBNNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL29618843 | 0.65 | CYP11B1 (0.41) | CYP11B1CYP11B2PDE3BPDE3ACYP2C9 | |
| SCHEMBL5944129 | 0.65 | — | — | |
| SCHEMBL1494651 | 0.64 | MAOB (0.44) | CYP11B1CYP11B2PDE3BPDE3AHTT | |
| SCHEMBL6099018 | 0.64 | NPC1 (0.45) | CRBNNPC1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104277039-A | Substitute butynyl-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| CN-104277039-A | Substitute butynyl-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| CN-104277040-A | Acyl piperazinone substituent-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| CN-104277041-A | Methyl substituted aromatic ring substituent-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| CN-104277041-A | Methyl substituted aromatic ring substituent-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| CN-104277037-A | Spiro-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| CN-104277038-A | Oxime substituent-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| CN-104277038-A | Oxime substituent-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| CN-104277040-A | Acyl piperazinone substituent-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| CN-104277037-A | Spiro-containing pyrazolopiperidone compound and composition and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-01-14 | — | — | CN | disclosed |
| EP-1140941-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004083177-A2 | LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20030069237-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | FEVIG JOHN M (US) | 2003-04-10 | — | — | US | disclosed |
| EP-1296982-A1 | 1-(HETEROARYL-PHENYL)-CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6506771-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-14 | — | — | US | disclosed |
| US-20020119986-A1 | Heteroaryl- phenyl heterobicyclic factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | disclosed |
| US-6413980-B1 | INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2002000655-A1 | 1 - (HETEROARYL-PHENYL) - CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| EP-1140941-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039131-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069237-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | F12, F11, F10 | CRBN 2790/4885NPC1 2063/4885MAPK13 2210/4885 |
| US-20020119986-A1 | Heteroaryl- phenyl heterobicyclic factor Xa inhibitors | SERPINC1, TFPI, F12 | CRBN 3480/4885NPC1 1610/4885MAPK13 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.